Investor Presentaiton

Hematology Reblozyl BET Inhibitor Breyanzi golcadomide Abecma alnuctamab GPRC5D iber/mezi Registrational trial to be initiated 1H 2024 .. Quadruple class exposed IMID, PI, anti-CD38, anti-BCMA Demonstrate high ORR and DOR in a high-need population Explore novel combinations CELMODs or anti-BCMA TCE Expand development with combinations in earlier disease setting Expand in 2L+ vs SOC Key segment in RRMM Potential to explore head-to- head study vs standard therapies Registrational Trial Ill Bristol Myers Squibb™ Additional studies planned in 2024+ Not for Product Promotional Use 89

View entire presentation